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ABSTRACT
Adverse drug reactions (ADRs) induced from high-order drug-drug
interactions (DDIs) due to polypharmacy represent a significant
public health problem. In this paper, we formally formulate the
to-avoid and safe (with respect to ADRs) drug recommendation
problems when multiple drugs have been taken simultaneously. We
develop a joint model with a recommendation component and an
ADR label prediction component to recommend for a prescription
a set of to-avoid drugs that will induce ADRs if taken together
with the prescription. We also develop real drug-drug interaction
datasets and corresponding evaluation protocols. Our experimental
results on real datasets demonstrate the strong performance of the
joint model compared to other baseline methods.
CCS CONCEPTS
•Computingmethodologies→Machine learning; Supervised
learning; • Applied computing → Health care information
systems; Health informatics; Bioinformatics; • Information
systems→ Data mining;
KEYWORDS
Adverse Drug Reaction, Polypharmacy, Drug Recommendation
1 INTRODUCTION
Adverse drug reactions (ADRs) induced from high-order drug-drug
interactions (DDIs) due to polypharmacy (i.e., simultaneous use of
multiple drugs) represent a significant public health problem. ADRs
refer to undesired or harmful reactions due to drug administration.
One of the major causes for ADRs is DDIs, which happen when
the pharmacological effects of a drug are altered by the actions
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of another drug, leading to unpredictable clinical consequences.
DDIs were responsible for approximately 26% of the ADRs, affected
50% of inpatients [14], and caused nearly 74,000 emergency room
visits and 195,000 hospitalizations annually in the US [13]. The
increasing popularity of polypharmacy continues to expose a sig-
nificant and growing portion of the population to unknown or
poorly understood DDIs and associated ADRs. The National Health
and Nutrition Examination Survey [5] reports that more than 76%
of the elderly Americans take two or more drugs every day. Another
study [8] estimates that about 29.4% of elderly American patients
take six or more drugs every day. This has made understanding
high-order DDIs and their associated ADRs urgent and important.
Current research on DDIs and their associated ADRs is primarily
focused on mining and detecting DDIs for knowledge discovery
(literature review in Section 2.1). In applying the knowledge in
practice for preventive, proactive and person-centered healthcare,
it also requires predictive power to deal with unknowns and un-
certainties, and to provide evidence-based suggestions to facilitate
future drug use. As wet-lab based experimental validation scheme
for DDI study still falls behind due to its low throughput and lack
of scalability, but meanwhile huge amounts of electronic medical
record data become increasingly available, data-driven computa-
tional methodologies appear more appealing to tackle DDI and ADR
problems. Unfortunately, computational effects to facilitate future
polypharmacy, particularly to assist safe multi-drug prescription,
are still in their infancy.
In this paper, we present a computational method toward the goal
of assisting future safe multi-drug prescriptions. Here we use the
term “prescription” to represent a set of drugs that have been taken
together, even though there could be non-prescription drugs. Thus,
we tackle the following to-avoid drug recommendation problem and
safe drug recommendation problem.
Definition 1. To-avoid Drug Recommendation: given the mul-
tiple drugs in a prescription that have been taken simultaneously,
recommend a short ranked list of drugs that should be avoided taking
together with the prescription in order to avoid a particular ADR.
Definition 2. Safe Drug Recommendation: given the multiple
drugs in a prescription that have been taken simultaneously, rec-
ommend a short ranked list of safe drugs that, if taken together with
the prescription, are not likely to induce a particular ADR.
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Please note that in this study we only consider one ADR and thus
drug safety is only considered with respect to that ADR. To the best
of our knowledge, this is the first work to formally formulate the
above problems and provide a computational solution framework.
The above two recommendation problems are significant par-
ticularly for healthcare practice. They can enable evidence-based
suggestions to help polypharmacy decision making, and induce
novel hypotheses on new high-order DDIs and associated ADRs.
These problems are different from traditional product recommen-
dation problems in e-commerce, in which no label information is
involved on a set of user’s previous purchased products as a whole
(each product is analogous to a drug; a set of previous purchased
products is analogous to a prescription). In addition, ADRs induced
from a set of drugs could be due to pharmaceutical, pharmacoki-
netic or pharmacodynamic interactions among only a (unknown)
subset of the drugs. In e-commerce recommendation problems, the
notion of subset synergy and interactions is very weak. Due to the
above reasons, the to-avoid drug recommendation and safe drug
recommendation problems are inherently very non-trivial.
Our contributions to solving the two new drug recommendation
problems are summarized as follows:
• We developed a joint sparse linear recommendation and logis-
tic regression model (SlimLogR), with a drug recommendation
component and an ADR label prediction component (Section 5).
The recommendation component captures drug co-prescription
patterns among ADR and non-ADR inducing prescriptions, re-
spectively, and uses such patterns to recommend drugs. The
ADR label prediction component re-ranks all the recommended
drugs based on their ADR probabilities to produce final recom-
mendations. These two components are learned concurrently
in SlimLogR so that the recommended drugs are more likely to
introduce expected ADR labels.
• We developed a protocol to mine high-order DDIs and their
associated ADRs, and provided a DDI dataset to the public 1
(Section 7).
• We developed new evaluation protocols and evaluation metrics
to evaluate the performance of drug recommendation (Section 8).
• We conducted comprehensive experiments to evaluate SlimLogR,
and provided case study on recommended drugs (Section 9). Our
experiments demonstrate strong performance of SlimLogR com-
pared to other methods.
2 RELATEDWORK
2.1 DDI and ADR Study
Significant research efforts have focused on detecting DDIs. These
efforts can be broadly classified into four categories [17]. Methods
of the first category analyze medical literature and/or electronic
medical records, and extract mentioned drug pairs [8]. Methods in
the second category integrate various biochemical and molecular
drug/target data tomeasure drug-drug similarities and score/predict
pairwise DDIs. These data include target information [17], pheno-
typic and genomic information [2], and drug side effects [16], etc.
Methods of the third category leverage healthcare information
on social media and online communities to detect DDIs [19]. The
1The dataset will be publicly available upon the acceptance of this paper
fourth category focuses on using numerical models to predict the
dose responses to multiple drugs [3]. A recent thread is dedicated
to understanding the interaction patterns among high-order DDIs,
and how such patterns can relate to induced ADRs [12].
2.2 Recommender Systems
Top-N recommender systems, which recommend the top-N items
that are most likely to be preferred by users, have been used in
a variety of applications in e-commerce, social networking and
healthcare, etc. The methods can be broadly classified in two cate-
gories. The first category is the neighborhood-based collaborative
filtering methods [11], which produce recommendations based on
similar users or similar items. The second category is model-based
methods, particularly latent factor models [15] that factorize the
user-item matrix into (low-rank) user factors and item factors, and
predict user preference over items using the latent factors. Recent
recommender systems have also been advanced by the significant
contribution from deep learning [21], where user preferences and
item characteristics can be learned in deep architectures. On the
other hand, recommender systems methods have also been inte-
grated with regression methods to tackle joint problems of missing
value recovery and prediction [9].
Recommender systems have been recently applied to prioritizing
healthcare information, due to a tremendous need for personalized
healthcare [18]. Current applications along this line include rec-
ommending physicians to patients on specific diseases [7], recom-
mending drugs for patient symptoms [20], recommending nursing
care plans [4], and therapy decision recommendation [6]. However,
to the best of our knowledge, very little research has been done on
new prescription recommendation particularly with ADR concerns.
3 DEFINITIONS AND NOTATIONS
In this paper, we use d to represent a drug, and a binary matrix
A ∈ Rm×n to represent prescription data. Each row of A represents
a prescription, denoted as ai (i = 1, · · · ,m), and each column of A
corresponds to a drug. Thus, there arem prescriptions and n drugs
in total represented by A. If a prescription ai contains a drug d j ,
the j-th entry in ai (i.e., ai, j ) will be 1, otherwise 0. Thus, ai is a
binary row vector representing the existence of drugs in the i-th
prescription. Note that all the prescriptions are unique in A. Drug
dosage in prescriptions is not considered in this study. When no
ambiguity arises, the terms “a prescription” and “a binary vector a”
are used exchangeably, and “a set of prescriptions” and “a matrix
A” are also used exchangeably. In addition, a label yi is assigned
to ai to indicate whether ai induces a certain ADR (denoted as
yi = 1 or y+i ) or not (denoted as yi = −1 or y−i ). In this paper, we
only consider one ADR and thus the labels are binary. In addition,
superscript + indicates information/data related to ADR induction
(i.e., positive information), superscript − indicates information/data
related to no ADR induction (i.e., negative information) and accent
A˜ indicates estimated A.
4 BACKGROUND
4.1 SLIM for top-N Recommendation
Sparse Linear Method (SLIM) [10] is an efficient and state-of-the-art
algorithm for top-N recommendation that was initially designed
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for e-commerce applications. In the drug recommendation problem,
given a drug prescription ai , SLIM models the score of how likely
an additional drug d j should be co-prescribed with ai as a sparse
linear aggregation of the drugs in ai , that is,
a˜i j = aiw
⊺
j , (1)
where a˜i j is the estimated score of d j in ai (can have values rather
than 0 and 1), and w⊺j is a sparse column vector of aggregation
coefficients. Note thatai j = 0, that is,d j is not includedai originally.
Drugs with high scores calculated as above will be recommended to
the prescription. Thus, the scores are referred to as recommendation
scores, and a prescription composed of ai and a recommended
drug d j is referred to as a new prescription with respect to ai ,
denoted as ai ∪ {d j }. The intuition of using SLIM for to-avoid drug
recommendation will be discussed later in Section 5.1.1.
To learnW = [w⊺1 ,w⊺2 , · · · ,w⊺n ], SLIM solves the following opti-
mization problem,
min
W
SLIM(A;W ,α , λ) = 12 ∥A −AW ∥
2
F +
α
2 ∥W ∥
2
F + λ∥W ∥ℓ1 ,
subject to W ≥ 0, diag(W ) = 0,
(2)
where ∥W ∥ℓ1 =
∑n
i=1
∑n
i=1 |wi j | is the entry-wise ℓ1-norm ofW ,
and ∥·∥F is the matrix Frobenius norm. The SLIM formulation can
also be considered as a way to reconstruct A by itself through
learning the patterns (i.e.,W ) in A. Therefore,W converts a binary
A into its estimation A˜ of floating values, which cover recover
unseen non-zero entries in A.
4.2 Logistic Regression for Label Prediction
We can formulate the problem of predicting whether a prescription
of multiple drugs induces a particular ADR as a binary classification
problem, and solve the problem using logistic regression (LogR).
In LogR, the probability of a prescription ai inducing the ADR is
modeled as follows,
p(yi |ai ;x , c) = (1 + exp(−yi (aix⊺ + c)))−1, (3)
where x⊺ and c are the parameters. To learn the parameters, LogR
solves the following optimization problem,
min
x ,c
LogR(y |A;x , c, β ,γ )
=
∑m
i=1log{1 + exp[−yi (aix
⊺ + c)]} + β2 ∥x ∥
2
2 + γ ∥x ∥1,
(4)
wherey = [y1;y2; · · · ,ym ], ∥x ∥1 = ∑ni=1 |xi |, and ∥x ∥22 = ∑ni=1 xi 2.
5 DRUG RECOMMENDATION
5.1 Joint Sparse Linear Recommendation and
Logistic Regression Model
We propose a novel model to conduct the task of to-avoid and safe
drug recommendation to existing prescriptions. The model recom-
mends a set of additional to-avoid drugs to an existing prescription
such that each of the recommended drugs should not be taken
together with the prescription in order to avoid ADRs. The model
also recommends safe drugs that can be taken together with the
prescription. This novel model consists of a drug recommendation
component and an ADR prediction component. The recommenda-
tion component is instantiated from SLIM (Section 4.1), and the ADR
prediction component uses logistic regression LogR (Section 4.2).
This model is referred to as joint sparse linear recommendation and
logistic regression model and denoted as SlimLogR.
SlimLogR learns the SLIM and LogR components jointly through
solving the following optimization problem.
min
W +,W −, x , c
SLIM(A+;W+,α , λ) + SLIM(A−;W −,α , λ)
ω{LogR(y+ |A˜+ ◦M+;x , c, β,γ )+
ω{LogR(y− |A˜− ◦M−;x , c, β,γ )}
subject to A˜+ = A+W +, A˜− = A−W −,
W + ≥ 0,W − ≥ 0, diag(W +) = 0, diag(W −) = 0.
(5)
In SlimLogR, A+/A− is a set of training prescriptions known to in-
duce ADRs/not to induce ADRs, respectively, and A˜+/A˜− is the
respective estimation from a SLIM model (Equation 1), that is,
A˜+ = A+W + and A˜− = A−W −, whereW + andW − are the SLIM
model parameters. In addition,M is a mask matrix that selects val-
ues in A˜ in predicting y (i.e., the ADR labels on A prescriptions) in
the LogR component, and ◦ is the entry-wise Hadamard product.
5.1.1 Learning Co-Prescription Patterns via SLIM. SlimLogR learns
drug co-prescription patterns using SLIM (a˜ = aW ,W ≥ 0, diag(W ) =
0, or explicitly, a˜i, j =
∑
k,k,j ai,kWk, j ), that is, whether a drug
should be included in a prescription is modeled as a linear function
of other drugs that are included in the prescription. This modeling
scheme is motivated by the existence of strong co-prescription drug
pairs as we observe from real data (Section 9.4). Meanwhile, linear-
ality is a simplistic relation to model the co-prescription patterns, in
which larger coefficients represent stronger co-prescription relation.
Note that the zero-diagonal constraint on the coefficient matrixW
in SLIM (i.e., diag(W +) = 0, diag(W −) = 0 in Equation 5) excludes
the possibility that a drug is co-prescribed with itself. In addition,
the non-negativity constraint onW (i.e.,W + ≥ 0,W − ≥ 0 in Equa-
tion 5) ensures that the learned relation is on drug co-appearance.
The regularization term ∥W ∥ℓ1 induces sparsity inW because not
all the drugs tend to be co-prescribed.
In SlimLogR, the patterns in ADR inducing and non-ADR in-
ducing prescriptions are modeled using two SLIM models (i.e.,
A˜+ = A+W + and A˜− = A−W −) because it is expected these two pat-
terns are different, and thus the prospectively learnedW + andW −
will present different patterns. The pattern difference is indicated
during the data pre-processing (Section 7.1 and 7.2, Table 2). TheW
coefficients in the SLIM component are learned by minimizing the
difference between A and A˜ estimated from SLIM. Note that A is a
binary matrix but A˜ can have floating values rather than 0 and 1.
Once the linear aggregation parameterW is learned, it can be used
to recommend additional drugs that are likely to be co-prescribed
with an existing prescription.
5.1.2 Predicting ADR via LogR. SlimLogR uses LogR to predict
whether a prescription will induce ADRs or not (i.e.,
∑m
i=1 log{1 +
exp[−yi ((a˜i ◦mi )x⊺ + c)}). LogR produces a probability of ADR
induction from a linear combination of drugs in a prescription
(Equation 3), and these probabilities can be further used to rank such
prescriptions. Note that the estimated prescriptions A˜ from SLIM
rather than A is used to train LogR. This connects SLIM and LogR
to further enforce that the SLIM component learns co-prescription
patterns that better correlate with their ADR induction labels (i.e.,y
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in Equation 5). Meanwhile, the use of A˜ also generalizes the ability
of LogR to predict for new prescriptions, as A˜ will have new drugs
compared to A (as discussed in Section 4.1).
In LogR, M selects values in A˜ in predicting y. We have the
following two approaches to selectingM+ andM−.
Inclusive SlimLogR (SlimLogRin): In this approach,M = 1 (i.e.,
a matrix of all 1’s), and therefore, all the drugs in A˜ and their values
will be used in the LogR component. The use of all these drugs
plays the role to enforce that the SLIM component produces large
recommendation scores on prescribed drugs in A and small scores
on un-prescribed drugs. In this way, the prescribed drugs will domi-
nate the label prediction in the LogR component in order to produce
accurate label prediction. This approach is referred to as inclusive
SlimLogR and denoted as SlimLogRin.
Exclusive SlimLogR (SlimLogRex): In this approach, M = I(A)
where I is an indicator function ((I )(x) = 0 if x = 0, 1 otherwise),
that is, only the prescribed drugs in A and their values are used to
ensure that LogR is able to make accurate prediction. This approach
is referred to as exclusive SlimLogR and denoted as SlimLogRex.
5.2 Training SlimLogR
The optimization problem 5 can be solved through the alternating
direction method of multipliers (ADMM) [1]. We introduce a new
variable Z and thus the following augmented Lagrangian as the
new objective to optimize:
min
W +,W −,Z+,Z−, x , c
L(W +,W −,Z+,Z−, x , c, u+, u−, ρ+, ρ−) =
SLIM(A+;W+,α , λ) + SLIM(A−;W −,α , λ)
ω{LogR(y+ |B˜+ ◦M+;x , c, β ,γ )+
ω{LogR(y− |B˜− ◦M−;x , c, β ,γ )}
u+⊺v+ +
ρ+
2 ∥v
+∥22 + u−⊺v− +
ρ−
2 ∥v
−∥22 ,
subject to B˜+ = A+Z+, B˜− = A−Z−,
v+ = vec(W +) − vec(Z+),v− = vec(W −) − vec(Z−),
W + = Z+,W − = Z−,W + ≥ 0,W − ≥ 0,
diag(W +) = 0, diag(W −) = 0,
where u+ and u− are the Lagrange multipliers; ρ+, ρ− > 0 are the
penalty parameters, and vec(·) is the vectorization of a matrix. The
algorithm to solve the problem is presented in Algorithm 1.
In Algorithm 1, to solve forW , the problem boils down to a
regularized least squares problem and can be solved by gradient
descent method. To solve for Z , the problem boils down to a com-
bination of a regularized logistic regression problem and a least
squares problem and can be solved by gradient descent method. To
solve for x and c , the problem boils down to a regularized logistic
regression problem and can be solved by gradient descent method.
The algorithm empirically converges.
5.3 Applying SlimLogR
SlimLogR recommends drugs for each existing prescription a fol-
lowing a two-step procedure:
• Step 1: use the learned SLIM component to recommend a list of
potential to-avoid/safe drug candidates {dr j };
Algorithm 1 Learning SlimLogR
1: function SlimLogR(A, ω , α , λ, β , γ )
2: ρ+ = 10, ρ− = 10, u+(0) = 0, u
−
(0) = 0, k = 0
3: Z+(0) =W
+
(0), Z
−
(0) =W
−
(0)
4: learnW +(0) andW
−
(0) from SLIM (Section 6.3)
5: learn x (0) and c(0) from LogR (Section 6.2)
6: while not converge do
7: {W +(k+1),W −(k+1) } B argmin
W +,W −
L(W +(k ),W −(k ), Z+(k ), Z−(k ),
W +(k+1) Bargmin
W +
x (k ), c(k ), u+(k ), u
−
(k ))
8: {Z+(k+1), Z−(k+1) } B argmin
Z+,Z−
L(W +(k+1),W −(k+1), Z+(k ), Z−(k ),
Z+(k+1) Bargmin
Z+
x (k ), c(k ), u+(k ), u
−
(k ))
9: { x (k+1), c(k+1) } B argmin
x , c
L(W +(k+1),W −(k+1), Z+(k+1), Z−(k+1),
{ x (k+1), c(k+1) } x (k ), c(k ), u+(k ), u−(k ))
10: u+(k+1) = u
+
(k ) + ρ
+(vec(W +(k+1) − Z+(k+1))
11: u−(k+1) = u
−
(k ) + ρ
+(vec(W −(k+1) − Z−(k+1))
12: k = k + 1
13: end while
14: returnW +(k+1),W
−
(k+1), Z
+
(k+1), Z
−
(k+1), x (k+1) and c(k+1)
15: end function
• Step 2: for each recommended candidate dr j , combine it with a
(i.e., a ∪ {dr j }) and use the learned LogR component to predict
the ADR probability of the new prescription.
Note that in LogR prediction, each recommended drug from SLIM
is considered individually together with the prescription. It is also
possible in real practice that multiple drugs all together should be
avoided as they, together with the prescription, may induce ADRs.
However, this problem is significantly more difficult as the synergy
of high-order drug combinations is highly non-trivial to estimate.
This problem will be tackled in our future research.
5.3.1 Recommendation from SLIM. Given a prescription a, the
recommendation scores of all drugs with respect to a are calculated
as a˜+ = aW + and a˜− = aW −, that is, a˜+, the scores of being
potential to-avoid drugs, are calculated fromW +, and a˜−, the scores
of being potential safe drugs, are calculated fromW −. Based on a˜+
and a˜−, the top-M scored drugs that are not in prescription a will
be selected as to-avoid and safe drug candidates for a, respectively.
5.3.2 ADR Prediction and re-Ordering from LogR. The to-avoid
and safe drug candidates from SLIM are further predicted using
LogR. For a prescription ai , each of its candidates will be com-
bined with ai to form a new candidate to-avoid or safe prescrip-
tion, denoted as r i (j)+ (i.e., r i (j)+ = a+i ∪ {d+r j }) and r i (j)− (i.e.,
r i (j)− = a−i ∪ {d−r j }) (j = 1, · · · ,N ), respectively. Note that here
r i (j)+ and r i (j)− are both binary vectors. They have their corre-
sponding score vectors from a˜+ and a˜−, denoted as si (j)+ and si (j)−,
respectively. Using f i (j)+ to represent either r i (j)+ or si (j)+, and
f i (j)− to represent either r i (j)− or si (j)−, the ADR probabilities are
calculated as p(y+ | f i (j)+;x , c) and p(y− | f i (j)−;x , c) (Equation 3).
That is, the to-avoid/safe drug candidates are only predicted for
their labels as being true to-avoid/safe drugs. The drug candidates
are then sorted based on their LogR prediction scores, respectively,
and the top-N ranked drugs will be recommended. Thus, the SLIM
step can be considered as an initial top-M recommendation and the
LogR step can be considered as a secondary re-ordering of initial
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candidates for final recommendations. If f i (j) = r i (j), the predic-
tion method is referred to as content-based prediction and denoted
as LogRb. If f i (j) = si (j), the prediction method is referred to as
score-based prediction and denoted as LogRs.
6 COMPARISON METHODS
6.1 Random Method (Rand)
In the first comparison method, we fully randomly recommend
drugs for each prescription as to-avoid drugs and safe drugs, respec-
tively. This method is referred to as random method and denoted
as Rand. Rand serves as a baseline in which no learning is involved.
6.2 Logistic Regression Only (LogR)
In this comparison method, only a LogR model is learned to predict
ADR labels. Prescriptions that induce ADRs are used as positive
training data, and prescriptions that do not induce ADRs are used as
negative training data. No SLIM models are learned in this method.
For a prescriptiona, each of all possible drugs that are not ina is first
combined with a to form a new prescription. Then LogR is applied
on the new prescription and produces a score of inducing ADRs.
The drugs that lead to the highest/lowest prediction scores are
recommended as the to-avoid/safe drugs. This method is referred
to as logistic regression only and denoted as LogR.
6.3 Sparse Linear Method Only (SLIM)
In this method, a SLIM+ model is learned on ADR inducing pre-
scriptions, and a SLIM− model is learned on non-ADR inducing
prescriptions. For a prescription, the top drugs recommended from
SLIM+ are considered as to-avoid drugs, and the top drugs recom-
mended from SLIM− are considered as safe drugs. This method is
referred to as SLIM only and denoted as SLIM.
6.4 Separate Models (SLIM+LogR)
In this method, a SLIM and a LogR model are built separately, and
used together for recommendation. Specifically, a SLIM+ and a
SLIM− as in SLIM only are learned first. Meanwhile, a LogR model
is also learned independently. The top recommendations from
SLIM+/SLIM− are then predicted using the LogR model, and the
top-scored drugs are recommended as to-avoid/safe drugs. That is,
the recommendation process of this method is identical to that of
SlimLogR. The difference is that SLIM and LogR are learned inde-
pendently, not jointly as in SlimLogR. This method is referred to
as separate SLIM-LogR model and denoted as SLIM+LogR.
7 MATERIALS
7.1 Mining Prescriptions
We first extracted high-order drug combinations from FDA Adverse
Event Reporting System (FAERS) 2. We use myopathy as the ADR
of particular interest, and extract 64,892 case (myopathy) events, in
which patients report myopathy after taking multiple drugs, and
1,475,840 control (non-myopathy) events, in which patients do not
report myopathy after taking drugs. Each of these events involves
2https://www.fda.gov/drugs/informationondrugs/ucm135151.htm
a combination of more than one drug. Each drug combination is
considered as a prescription.
Table 1: Contingency Table
OR = n1m1 /
n2
m2
ADR no ADR total
a n1 m1 n1 +m1
\a n2 m2 n2 +m2
total n1 + n2 m1 +m2 n1 + n2 +m1 +m2
Here, n1/m1 is the number of events where a is taken and ADR does/doesn’t occur;
n2/m2 is the number of events where a is not taken and ADR does/doesn’t occur.
Among all the involved prescriptions, 10,250 unique prescrip-
tions appear in both case and control events. For those 10,250 pre-
scriptions, we use Odds Ratio (OR) to quantify their ADR risks. The
OR for a prescription a is defined based on the contingency table 1,
and is the ratio of the following two values: 1). the odds that the
ADR occurs when a is taken (i.e., n1m1 in Table 1); and 2). the odds
that the ADR occurs when a is not taken (i.e., n2m2 in Table 1). OR < 1
indicates the decreased risk of ADR after a patient takes the pre-
scription, OR = 1 indicates no risk change, and OR > 1 indicates the
increased risk. In the 10,250 prescriptions, 8,986 prescriptions have
OR > 1 and 1,264 prescriptions have OR < 1. These two sets of
prescriptions are denoted as A+0 and A
−
0 , respectively. In addition to
these prescriptions, there are 27,387 unique prescriptions that only
appear in case events and 621,449 unique prescriptions that only
appear in control events. These two sets are denoted as A++ and A−−,
respectively. The set of prescriptions in case events is denoted as
A+ (i.e., A+ = A++ ∪A+0 ) and is used as the positive set. The set of
prescriptions in control events is denoted asA− (i.e.,A− = A−−∪A−0 )
and is used as the negative set. All these four sets together define
a prescription dataset from FAERS, denoted as AFAERS. Table 2
presents the statistics of AFAERS.
Table 2: Data Statistics
dataset stats A
− A+
A−− A−0 A
+
0 A
+
+
#{a } 621,449 1,264 8,986 27,387
#{d } 1,209 417 881 1,201
AFAERS avgOrd 6.100 2.351 3.588 7.096
avgFrq 1.761 225.317 13.730 1.402
avgOR - 0.546 16.343 -
#{a } 2,200 1,264 2,464 1,000
#{d } 562 417 692 679
A∗ avgOrd 2.678 2.351 3.809 7.615
avgFrq 42.082 225.317 20.565 5.520
avgOR - 0.546 31.998 -
Here, “#{a }” and “#{d }” represent the number of prescriptions and the number of
involved drugs, respectively. In each set of prescriptions, “avgOrd”/“avgFrq”/“avgOR”
is the average number of drugs/average frequency/average OR of all prescriptions.
Note that the reason for myopathy as the only ADR is that
myopathy has been well studied and well understood compared
to other ADRs in terms of the drugs and drug mechanisms that
induce myopathy. Such knowledge will well support retrospective
evaluation and validation on drug recommendation with respect
to myopathy. On the other hand, multiple ADRs will introduce
substantial difficulty to the recommendation problem, and thus will
be tackled in future research.
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7.2 Training Data Generation
As shown in Table 2,A++ andA+0 ofAFAERS have fewer prescriptions
than A−− and A−0 , and the prescriptions in A
+
+ are very infrequent.
To use more frequent and more confident prescriptions from case
events, we further pruned prescriptions from A++ and A+0 of AFAERS
as follows. From A++ of AFAERS, we retained the top 1,000 most
frequent prescriptions. For A+0 of AFAERS, we applied right-tailed
Fisher’s exact test on the prescriptions to test the significance of
their ORs at 5% significance level and retained prescriptions with
statistically significant ORs. Thus, the pruned A++ and A+0 contain
statistically confident prescriptions, which are very likely to induce
myopathy, and therefore, these prescriptions are labeled as positive.
We retained all 1,264 the prescriptions in A−0 of AFAERS because
this set is not large and contains informative prescriptions that may
or may not induce myopathy. We further pruned A−− of AFAERS and
retained the topmost frequent prescriptions. The prescriptions from
A−0 and the prunedA
−− are labeled as negative. To make the positive
and negative training sets balance, we retained 2,200 prescriptions
from A−− of AFAERS. The pruned dataset from AFAERS is denoted as
A∗. Table 2 presents the description of A∗. Note that A∗ is the set
of labeled prescriptions that are used for model training.
Note that the prescriptions in A− do not induce myopathy, but
they may induce other ADRs because all prescriptions in FEARS
are reported as inducing ADRs. Therefore, A− is not truly negative
(i.e., free of ADRs) and only negative with respective to myopathy.
Similarly, when safe drugs are referred to, they represent safety in
terms of myopathy, but not necessarily free of any ADRs.
8 EVALUATION PROTOCOLS AND METRICS
8.1 Five-Fold Cross Validation
The performance of different methods is evaluated through five-fold
cross validation. The dataset A∗ is randomly split into five folds of
equal size (i.e., same number of prescriptions). Four folds are used
for model training and the rest fold is used for testing. In the fold
for testing, one drug is randomly selected and removed from each
prescription. If the prescription after drug removal actually induces
ADRs, it is removed from the testing set. Then the to-avoid/safety
drugs will be recommended for the rest of the prescription. This is to
make sure that it is the recommended to-avoid drugs that introduce
DDIs and thus ADRs. This process is performed five times, with
one fold for testing each time. The final result is the average out of
the five experiments. In each split, the corresponding training set
is denoted as A∗trn , and the testing set is denoted as A∗tst .
8.2 Knowledge Pool Generation
To evaluate the performance of various methods, we first define a
knowledge pool of labeled prescriptions, denoted as Apool , which
the recommended new prescriptions can be searched from and
evaluated against. This knowledge pool serves as the entire knowl-
edge space which is unknown during training. For a particular
training set A∗trn , Apool can be either A∗ \A∗trn (i.e., Apool is
actually A∗tst in this case) or AFAERS \A∗trn (i.e., Apool is much
larger than A∗tst ). Note that A∗trn is excluded from Apool because
we can always search testing prescriptions in A∗trn (i.e., known
labeled prescriptions) in order to identify corresponding to-avoid
prescriptions in A∗trn , and therefore no recommendations will
be needed. By excluding A∗trn from Apool , we care about recom-
mending particularly to-avoid/safe drugs to prescriptions such the
new prescriptions have not been observed before. We believe this
application is of more interest and significance in real practice.
8.3 Evaluation Metrics
Each of the methods will generate N recommended to-avoid/safe
drugs for each testing prescription. Given Apool , the performance
of these methods is evaluated using the following three metrics.
Normalized Truncated Recall (rect) is denoted as rect and de-
fined as follows,
rect =
#TP
#P , rect =
rect
max(rect) , (6)
where #TP is the number of recommended to-avoid prescriptions for
testing prescriptions that appear in Apool+, and #P is the number
of all to-avoid prescriptions for testing prescriptions in Apool+.
Note that the maximum possible value of rect (max(rect)) can be
smaller than 1. This is because for each testing prescription, the
number of its true to-avoid prescriptions existing inApool+ (i.e., #P)
can be more than the number of recommended prescriptions (i.e.,
N ) that is allowed and therefore more than #TP. Note that for each
testing prescription, only top-N to-avoid drugs are recommended,
where N is a small number.
Normalized Truncated Precision (prect) is denoted as prect and
defined as follows
prect =
#TP
#TP + #FP , prect =
prect
max(prect) , (7)
where #FP is the number of recommended to-avoid prescriptions
for testing prescriptions that are not in Apool+, and thus #TP+ #FP
is the number of total recommended to-avoid prescriptions. Note
that the maximum possible value of prect can be smaller than 1.
This is because for each testing prescription, the number of its true
to-avoid prescriptions existing in Apool+ (i.e., #P) can be smaller
than the number of recommended prescriptions (i.e., N ) that is
allowed, and therefore #TP is smaller than #TP + #FP.
Normalized Truncated Accuracy (acct) is denoted as acct and
calculated as follows,
acct =
#TP + #TN
#TP + #TN + #FP + #FN , acct =
acct
max(acct) , (8)
where #TN/#FN is the number of recommended safe prescriptions
that do exist/do not exist inApool−. Note that themaximumpossible
value of acct can be smaller than 1. This is due to a similar reason
as for prect < 1, that is #TP can be smaller than #TP + #FP, and
#TN can be smaller than #TN + #FN.
Note that we did not use conventional ranking-based metrics
such as average precision at k because we believe in clinical practice
of multi-drug prescription, people care whether all the to-avoid
drugs can be correctly recommended (i.e., a notion of recall) much
more than how the to-avoid drugs are ranked.
9 EXPERIMENTAL RESULTS
The presented experimental results in this section are more focused
on to-avoid drug recommendation due to space limit. In addition,
to-avoid drug recommendation is of more clinical significance com-
pared to safe drug recommendation.
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9.1 Method Comparison
Table 3: Comparison based on the Best rect (N = 5)
Apool mdl prd rect prect acct
AFAERS
SlimLogRin
LogRs 0.2361 0.2361 0.2958
LogRb 0.2361 0.2361 0.2958
SlimLogRex
LogRs 0.2108 0.2108 0.2795
LogRb 0.2108 0.2108 0.2795
Rand - 0.0060 0.0118 0.0238
LogR - 0.2082 0.2081 0.2430
SLIM - 0.2127 0.2126 0.2811
SLIM+LogR - 0.2127 0.2126 0.2813
A∗
SlimLogRin
LogRs 0.2618 0.2615 0.2815
LogRb 0.2618 0.2615 0.2815
SlimLogRex
LogRs 0.2479 0.2479 0.2748
LogRb 0.2479 0.2479 0.2748
Rand - 0.0029 0.0059 0.0034
LogR - 0.1780 0.1781 0.1032
SLIM - 0.2469 0.2467 0.2754
SLIM+LogR - 0.2469 0.2467 0.2754
The column “mdl” corresponds to models. The column “prd” corresponds to predic-
tion methods. The best rect is underlined. The best overall performance is bold.
Table 4: Comparison based on the Best prect (N = 5)
Apool mdl prd rect prect acct
AFAERS
SlimLogRin
LogRs 0.2361 0.2361 0.2958
LogRb 0.2361 0.2361 0.2958
SlimLogRex
LogRs 0.2108 0.2108 0.2795
LogRb 0.2108 0.2108 0.2795
Rand - 0.0060 0.0118 0.0238
LogR - 0.2082 0.2081 0.2430
SLIM - 0.2127 0.2128 0.2809
SLIM+LogR - 0.2127 0.2128 0.2811
A∗
SlimLogRin
LogRs 0.2613 0.2615 0.2821
LogRb 0.2613 0.2615 0.2821
SlimLogRex
LogRs 0.2477 0.2479 0.2759
LogRb 0.2477 0.2479 0.2759
Rand - 0.0029 0.0059 0.0034
LogR - 0.1780 0.1781 0.1032
SLIM - 0.2465 0.2467 0.2754
SLIM+LogR - 0.2465 0.2467 0.2754
The column “mdl” corresponds to models. The column “prd” corresponds to predic-
tion methods. The best prect is underlined. The best overall performance is bold.
Table 3, 4 and 5 present the performance of different methods in
terms of their best rect, best prect and best acct, respectively, and
the values on the other two evaluationmetrics when each respective
best performance is achieved. Optimal parameters are not presented
in the tables due to space limit. In these tables, SlimLogR first
recommends 20 drugs from its SLIM component, and then its LogR
component produces top-5 (i.e., N = 5) scored drugs as to-avoid
drug recommendations. In terms of best rect as in Table 3, when
AFAERS is used asApool , SlimLogRin achieves the best performance
(rect = 0.2361), which is 11.0% better than the second best method
SLIM and SLIM+LogR. When A∗ is used as Apool , SlimLogRin also
achieves the best performance (rect = 0.2618), which is 5.6% better
than the second best method SlimLogRex, and 6.0% better than
Table 5: Comparison based on the Best acct (N = 5)
Apool mdl prd rect prect acct
AFAERS
SlimLogRin
LogRs 0.2355 0.2355 0.2969
LogRb 0.2355 0.2355 0.2969
SlimLogRex
LogRs 0.2099 0.2099 0.2797
LogRb 0.2108 0.2108 0.2797
Rand - 0.0060 0.0118 0.0238
LogR - 0.2036 0.2039 0.2468
SLIM - 0.2019 0.2020 0.2830
SLIM+LogR - 0.2019 0.2020 0.2825
A∗
SlimLogRin
LogRs 0.2589 0.2592 0.2832
LogRb 0.2589 0.2592 0.2832
SlimLogRex
LogRs 0.2477 0.2479 0.2765
LogRb 0.2477 0.2479 0.2765
Rand - 0.0029 0.0059 0.0034
LogR - 0.1780 0.1781 0.1032
SLIM - 0.2434 0.2432 0.2776
SLIM+LogR - 0.2434 0.2432 0.2776
The column “mdl” corresponds to models. The column “prd” corresponds to predic-
tion methods. The best acct is underlined. The best overall performance is bold.
SLIM and SLIM+LogR. This indicates the power of joint learning of
SLIM recommendation component and LogR prediction component
in SlimLogR. Meanwhile, SlimLogR performs at least 39-fold better
than Rand on AFAERS as Apool , and at least 90-fold better on A∗ as
Apool . This indicates the strong ability of SlimLogR in discovering
true to-avoid drugs. On the other hand, LogR is a strong baseline
because it is at least 34-fold better and 61-fold better than Rand in
the twoApool cases. SLIM is even stronger than LogR in discovering
true to-avoid drugs, as it is 2.2% and 38.7% better than Rand in the
two Apool cases. However, when LogR or SLIM is used alone, they
are not any better than being used together in SLIM+LogR, whereas
the latter is still behind SlimLogR.
Very similar trends exist in Table 4 and 5. In terms of best prect
as in Table 4, SlimLogR outperforms the second best methods SLIM
and SLIM+LogR at 10.9% and 6.0% in the two Apool cases, respec-
tively. In terms of best acct as in Table 5, SlimLogR outperforms
the second best methods SLIM and SLIM+LogR at 4.9% and 2.0%
in the two Apool cases, respectively. More importantly, SlimLogR
achieves the overall best rect, best prect and best acct almost
at the same time. For example, when SlimLogRin achieves best
rect 0.2361 as in Table 3, its corresponding prect 0.2361 is its best
prect as in Table 4, and its corresponding acct 0.2958 is same as
its best acct 0.2958 in Table 5. This indicates the strong capability
of SlimLogR in accurately recovering true in-avoid drugs and also
true safe drugs.
It is notable in Table 3, 4 and 5 that SlimLogRin consistently out-
performs SlimLogRex in rect, prect and acct. SlimLogRin uses
all the drugs and their scores recommended by its SLIM component
in its LogR component, whereas SlimLogRex only uses the drugs
that are already in corresponding prescriptions and their scores by
SLIM in LogR. The use of all drugs from SLIM in LogR may enable
SlimLogR to better learn its SLIM component and better capture
the co-prescription relations among drugs that further lead to their
ADR labels. Meanwhile, it may generalize the capability of its LogR
component to better predict new prescriptions, not to overfit on
known prescriptions.
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It is also notable that the recommendation method LogRb and
LogRs (Section 5.3.2) do not make a significant difference. They
almost achieve identical performance given a certain SlimLogR
method as in Table 3, 4 and 5. This may be due to the fact that
the SLIM and LogR components together in SlimLogR are able to
recover strong co-prescription patterns that closely correlate to
prescription ADR labels, and thus the patterns have their recom-
mendation scores close to binary.
9.2 Parameter Study
Table 6, 7 and 8 present the parameter study on ω and α as in
Equation 5 on SlimLogRin with LogRs for top-5 (i.e., N = 5) to-
avoid drug recommendations. The pool Apool is set to AFAERS. In
SlimLogR,ω controls the weight of LogR component and α controls
the Frobenius-norm regularizations in SLIM component. We don’t
present the parameter study over other parameters here. This is
because in our study, it is observed that SlimLogR requires a very
small λ (i.e., the parameter for the ℓ1-norm regularizations in SLIM
component), for example, the optimal λ is 10−6. Also SlimLogR
requires small β and γ (i.e., the parameters for LogR component
regularization), for example, the optimal β is 10−6 and the optimal
γ is 10−2 . This indicates the very minor effects of these parameters
on SlimLogR. We fix the optimal values for these parameters in
Table 6, 7 and 8, and study the effects only from ω and α .
Table 6, 7 and 8 demonstrate a very similar trend, that is, as
ω becomes smaller (i.e., the weight on LogR component becomes
lower in SlimLogR), all rect, prect and acct first increase and then
decrease, and the optimal ω is around 5. This represents a trade-off
between the SLIM component and the LogR component in SlimLogR.
Empirically more weight should be put on the LogR component than
on SLIM component. This may indicate that ADR label prediction
is more difficult than co-prescription pattern learning. Similarly,
as α becomes smaller (i.e., the regularization on parameterW of
SLIM becomes less), all rect, prect and acct also first increase and
then decrease, and the optimal α is around [10, 50]. Smaller α will
introduce larger values inW compared to larger α , and thus the
relatively small optimal α indicates thatW captures strong patterns
from prescriptions.
9.3 Top-N Performance
Table 9 presents the performance of the optimal SlimLogRin with
LogRs when N = 5, 10, 20 to-avoid drugs are recommended. As
SlimLogRin recommends more to-avoid drugs, the performance
in terms of all rect, prect and acct increases. This indicates the
capability of SlimLogRin in correctly ranking true to-avoid drugs
in the top of its recommendations.
9.4 Co-Prescription Patterns
We considerW + andW − from SlimLogRin of the best performance
(i.e., ω = 5,α = 20).W +/W − captures the co-prescription patterns
among drugs that often appear in ADR inducing/no-ADR inducing
prescriptions, respectively. The learnedW + has a density 3.6%, and
its top-5 largest values correspond to the following drug pairs: (des-
ogestrel, ethinyl estradiol), (phenylephrine, hydrochlorothiazide),
(salmeterol, fluticasone propionate), (hydrocodone, acetaminophen),
(ethinyl estradiol, etonogestrel). These drug pairs are frequently pre-
scribed together inA+. The number of prescriptions inA+ that con-
tain these drug pairs is 38, 32, 44, 133 and 38, respectively, compared
to the average number ofA+ prescriptions of all possible drug pairs,
which is 1.22. Many of the co-prescribed drugs share similar medi-
cal purposes. For example, salmeterol and fluticasone propionate
are prescribed together to control and prevent symptoms caused by
asthma or ongoing lung disease. Ethinyl estradiol and etonogestrel
are prescribed together for birth control, as well as ethinyl estradiol
and desogestrel. Hydrocodone and acetaminophenare frequently
are taken together to treat pains and reduce fever.
The learnedW − has a density 0.8%, and its top-5 largest val-
ues correspond to the following drug pairs: (lopinavir, ritonavir),
(norelgestromin, ethinyl estradiol), (tenofovir, emtricitabine), (emtric-
itabine, tenofovir), (salmeterol, fluticasone propionate) These drug
pairs are also frequently co-prescribed in A−. The number of A−
prescriptions with these drugs pairs is 36, 23, 35, 35 and 35, respec-
tively, compared to 1.11, the average number ofA− prescriptions of
all possible drug pairs. These drugs pairs also share similar medical
purposes. For example, lopinavir and ritonavir, and tenofovir and
emtricitabine are commonly used in HIV cocktail therapy. Norelge-
stromin and ethinyl estradiol are co-prescribed for birth control.
In the corresponding learned x (i.e., the parameter in the LogR
component), the top-2 largest values correspond to drug simvastatin
and atorvastatin. These two drugs have been reported in SIDER
Side Effect Resource 3 as to induce myopathy. 28.72% of the ADR
inducing prescriptions have at least one of these two drugs.
9.5 Case Study
Table 10 presents some examples of prescriptions and their recom-
mended to-avoid drugs from SlimLogR such that the correspond-
ing new prescriptions are true positive. Drugs that are reported
in SIDER to induce myopathy are bold. Based on whether the pre-
scriptions have myopathy-inducing drugs or not, and whether the
recommended drugs induce myopathy or not, all the new prescrip-
tions can be classified into four categories (corresponding to the
four row blocks in Table 10). Note that in the last category, even
the prescriptions do not contain any myopathy-inducing drugs,
SlimLogR is able to recommend other non-ADR inducing drugs
such that the new prescriptions will induce myopathy. This demon-
strates the strong capability of SlimLogR for co-prescription pattern
learning and ADR label prediction.
10 DISCUSSIONS AND CONCLUSIONS
In this paper, we formally formulated the to-avoid drug recommen-
dation problem and the safe drug recommendation problem. We
developed a joint sparse linear recommendation and logistic regres-
sion model (SlimLogR) to tackle the recommendation problems,
and developed real datasets and new evaluation protocols to evalu-
ate the model. Our experiments demonstrate strong performance
of SlimLogR compared to other methods.
In SlimLogR, we use simplistic linear models. Non-linear models
(for both recommendation and label prediction) together may be
able to better discover co-prescription patterns and predict labels
jointly. We will investigate non-linear models in the future work.
3http://sideeffects.embl.de
Drug Recommendation toward Safe Polypharmacy KDD’18, August 2018 19-23, London, United Kingdom
Table 6: rect of SlimLogRin +LogRs (N = 5)
ω\α 100 50 20 10 5
20 0.2324 0.2344 0.2346 0.2349 0.2338
10 0.2315 0.2352 0.2349 0.2358 0.2344
5 0.2318 0.2355 0.2361 0.2361 0.2341
1 0.2315 0.2327 0.2321 0.2304 0.2290
Apool is AFAERS . The best performance is bold.
Table 7: prect of SlimLogRin +LogRs (N = 5)
ω\α 100 50 20 10 5
20 0.2325 0.2343 0.2347 0.2349 0.2339
10 0.2315 0.2351 0.2351 0.2359 0.2345
5 0.2321 0.2355 0.2361 0.2359 0.2341
1 0.2315 0.2327 0.2321 0.2305 0.2290
Apool is AFAERS . The best performance is bold.
Table 8: acct of SlimLogRin +LogRs (N = 5)
ω\α 100 50 20 10 5
20 0.2951 0.2919 0.2890 0.2895 0.2874
10 0.2943 0.2967 0.2938 0.2915 0.2891
5 0.2955 0.2969 0.2958 0.2951 0.2924
1 0.2938 0.2953 0.2936 0.2919 0.2893
Apool is AFAERS . The best performance is bold.
Table 9: Top-N Performance of SlimLogRin with LogRs
N
AFAERS A∗
rect prect acct rect prect acct
5 0.2358 0.2359 0.2915 0.2613 0.2615 0.28210.2324 0.2325 0.2929 0.2589 0.2592 0.2832
10 0.2497 0.2497 0.3076 0.3469 0.3467 0.34190.2467 0.2467 0.3110 0.3434 0.3432 0.3439
20 0.2885 0.2887 0.2762 0.4403 0.4407 0.40160.2694 0.2695 0.3289 0.4265 0.4273 0.4135
Column of “N” represents the number of recommended drugs. Columns of “AFAERS”
and “A∗” represent that “AFAERS” and “A∗” are used asApool , respectively. The bold
performance is the best under the corresponding metrics in each column.
Table 10: To-avoid Drug Recommendation Examples
recommendation prescription
pramipexole carbidopa, citalopram, alprazolam, levothyroxine,
entacapone, clonazepam, atorvastatin, levodopa
rosuvastatin niacin, simvastatin
phenytoin oxcarbazepine, levetiracetam
simvastatin ramipril, ranolazine, amlodipine, trimethoprim, nitro-
glycerin, acetylsalicylic acid, isosorbide mononitrate,
carvedilol, nicorandil
abacavir nelfinavir, tenofovir, zidovudine, ritonavir,
stavudine, lamivudine, didanosine, zalcitabine,
lopinavir
rosiglitazone metformin, simvastatin
alendronate vitamin c, triamterene, valdecoxib, lisinopril, deslo-
ratadine, hydrochlorothiazide, anastrozole
risperidone valproic acid, clozapine
Drugs that are reported in SIDER to induce myopathy are bold.
Also it is common that DDIs induce multiple ADRs simultaneously.
This problem is substantially more difficult but deserve future in-
vestigation.
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